SCHEMBL15216432

SCHEMBL15216432

CCCCCCCCCCCCCCCCCC(=O)OC(CCCCCCCC(=O)O)C(CC)S(=O)(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.48
FFAR1 O14842 2/20 0.48
LMNA P02545 2/20 0.45
GPR84 Q9NQS5 7/20 0.45
PPARG P37231 7/20 0.45
PPARD Q03181 7/20 0.45
PPARA Q07869 7/20 0.45
HDAC11 Q96DB2 5/20 0.45
TSHR P16473 4/20 0.45
PTPN1 P18031 3/20 0.45
ALDH1A1 P00352 2/20 0.45
TLR2 O60603 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
FABP4 P15090 2/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
SLC22A8 Q8TCC7 1/20 0.45
MEN1 O00255 1/20 0.45
ESR1 P03372 1/20 0.45
ALOX15 P16050 1/20 0.45
PDE4A P27815 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4397729 1.00 FFAR4 (0.48) FFAR4FFAR1LMNAGPR84PPARG
SCHEMBL17654948 0.93 FFAR4 (0.42) FFAR4FFAR1LMNAGPR84PPARG
SCHEMBL15216433 0.90 CA12 (0.46) LMNAPPARGPPARAALDH1A1MAPT
SCHEMBL17654946 0.86 LMNA (0.53) LMNATSHRALDH1A1MEN1KMT2A
SCHEMBL15198293 0.86 ALDH1A1 (0.49) FFAR4FFAR1LMNAPPARGPPARD
SCHEMBL24882733 0.84 FFAR4 (0.61) FFAR4FFAR1LMNAGPR84PPARG
SCHEMBL4414339 0.84 FFAR4 (0.61) FFAR4FFAR1LMNAGPR84PPARG
SCHEMBL4410097 0.84 FFAR4 (0.61) FFAR4FFAR1LMNAGPR84PPARG
SCHEMBL4405746 0.84 FFAR4 (0.61) FFAR4FFAR1LMNAGPR84PPARG
SCHEMBL15217202 0.83 CA12 (0.47) LMNAPPARGPPARAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170211016-A1 SYNERGISTIC SURFACTANT BLENDS STEPAN CO (US) 2017-07-27 US disclosed
US-20170211016-A1 SYNERGISTIC SURFACTANT BLENDS STEPAN CO (US) 2017-07-27 US disclosed
US-9688944-B2 Synergistic surfactant blends STEPAN COMPANY (US) 2017-06-27 US disclosed
US-9688944-B2 Synergistic surfactant blends STEPAN COMPANY (US) 2017-06-27 US disclosed
US-9598359-B2 Sulfonates from natural oil metathesis STEPAN COMPANY (US) 2017-03-21 US disclosed
US-9598359-B2 Sulfonates from natural oil metathesis STEPAN COMPANY (US) 2017-03-21 US disclosed
US-9303234-B2 Hard surface cleaners based on compositions derived from natural oil metathesis STEPAN COMPANY (US) 2016-04-05 US disclosed
US-20150094383-A1 SYNERGISTIC SURFACTANT BLENDS STEPAN CO (US) 2015-04-02 US disclosed
US-20150094383-A1 SYNERGISTIC SURFACTANT BLENDS STEPAN CO (US) 2015-04-02 US disclosed
WO-2013162924-A1 SYNERGISTIC SURFACTANT BLENDS STEPAN COMPANY (US) 2013-10-31 WO disclosed
US-20130225473-A1 SULFONATES FROM NATURAL OIL METATHESIS STEPAN COMPANY (US) 2013-08-29 US disclosed
US-20130225473-A1 SULFONATES FROM NATURAL OIL METATHESIS STEPAN COMPANY (US) 2013-08-29 US disclosed
US-20130225469-A1 HARD SURFACE CLEANERS BASED ON COMPOSITIONS DERIVED FROM NATURAL OIL METATHESIS STEPAN COMPANY (US) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225473-A1 SULFONATES FROM NATURAL OIL METATHESIS STS, SULT1E1, SULT1A1 FFAR4 238/4885FFAR1 38/4885LMNA 4164/4885
US-20150094383-A1 SYNERGISTIC SURFACTANT BLENDS HHAT, AADAT, SQLE FFAR4 100/4885FFAR1 51/4885LMNA 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.